Recently, the Deputy Secretary of the Yicheng Municipal Party Committee and Mayor of Yicheng City, Hubei Province, led a special inspection delegation to conduct an on-site inspection and guidance at Vcare PharmaTech, the headquarters of Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical). Focusing on the Phase II project construction and long-term future development plans of Tianshu Pharmaceutical, this inspection aims to gain an in-depth understanding of the enterprise’s development momentum, precisely meet the enterprise’s demands, deepen government-enterprise cooperation, and jointly promote the high-quality development of the pharmaceutical and health industry in Yicheng.
Learn MoreRecently, the Dapagliflozin Propylene Glycol Monohydrate API, independently developed and manufactured by Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical), has officially obtained the acceptance notice for the CEP to the European Pharmacopoeia issued by the EDQM. This milestone marks a crucial step forward for Tianshu Pharmaceutical in API R&D, registration, quality management and international compliance capabilities, further enhancing the company's competitiveness in the high-end API sector.
Learn More
On January 25, 2026, Yicheng City held the municipal Economic Work Conference and Three-level Cadres Conference. The commending ceremony recognized advanced collectives and individuals who made outstanding contributions to the city’s economic and social development in 2025.Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical) was awarded the honorary title of "Advanced Collective for County Economic Development 2025" for its outstanding performance and remarkable contributions in industrial upgrading, R&D innovation and county empowerment, standing as a backbone force driving economic growth in Yicheng’s biomedical industry. Liu Yunlong, General Manager of Tianshu Pharmaceutical, attended the conference as the enterprise representative and received the award on stage.
Learn More
Recently, the near-term greenhouse gas (GHG) emission reduction targets of Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutica) have been successfully validated by the Science Based Targets initiative (SBTi). This fully demonstrates the company's determination and confidence in actively responding to climate change and firmly practicing the ESG philosophy, marking a solid step forward for Tianshu Pharmaceutical on the path of low-carbon and sustainable development.
Learn MoreRecently, Hubei Tianshu Pharmaceutical Co., Ltd. (referred to as "Tianshu Pharmaceutical") has received the Approval Notice for Marketing Application of Chemical Active Pharmaceutical Ingredients (APIs) issued and verified by the National Medical Products Administration (NMPA). This marks the official approval for marketing of the company's first generic drug API — Vonoprazan Fumarate (Registration No.: Y20240000846), which is a milestone in the company's development.
Learn More
Recently, Hubei Tianshu Pharmaceutical Co., Ltd. Tianshu Pharmaceutical) and Yunzi Enterprise Management Consulting (Hebei) Co., Ltd. (Yunzi Pharmaceutical) held a strategic cooperation signing ceremony and project kick-off meeting. The two parties officially entered into strategic cooperation to comprehensively elevate Tianshu Pharmaceutical's quality management system, laying a solid foundation for the company to further expand international markets, boost product exports, and meet certification standards of high-end markets including the US, the EU and Japan.
Learn More